Literature DB >> 21649792

Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.

Jian-Qing Jiang1, Shan Lin, Peng-Cheng Xu, Zhen-Feng Zheng, Jun-Ya Jia.   

Abstract

AIM: Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been proposed to be the replacement of renal osteodystrophy by the Organization of Kidney Disease: Improving Global Outcomes since 2005 because the mineral disorder is not confined to the skeleton in CKD. Accordingly, laboratory and imaging tests have been emphasized for the clinical assessment of patients with CKD besides renal biopsy. The objective of the current study was to investigate whether osteoprotegerin (OPG) could be made a useful biomarker for early diagnosis of CKD-MBD.
METHODS: Sixty pre-dialysis patients with CKD 1-5 were enrolled in this study. The serum calcium, phosphorus, blood urea nitrogen, creatinine, alkaline phosphatase, Osteocalcin, Calcitonin, intact parathyroid hormone and OPG were measured. Bone mineral densities of the lumbar spine (L2-L4), femoral neck, Ward's triangle and trochanter were measured by dual-energy X-ray absorptiometry.
RESULTS: Among all measured serum bone metabolism indexes, the changing of serum OPG level happened at the earliest time (CKD 3) and its correlation coefficient with estimated glomerular filtration rate (eGFR) was also the highest (r = -0.601, P = 0.001). In the multivariable analysis that included sex, age and eGFR as controlling factors, the serum OPG correlated with the bone mineral density (BMD) of Ward's triangle (r = -0.390, P = 0.041).
CONCLUSION: Serum OPG may be a useful biomarker for early diagnosis of CKD-MBD.
© 2011 The Authors. Nephrology © 2011 Asian Pacific Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21649792     DOI: 10.1111/j.1440-1797.2011.01481.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  8 in total

Review 1.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

2.  Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.

Authors:  Pinar Demir; Fusun Erdenen; Hale Aral; Turker Emre; Sennur Kose; Esma Altunoglu; Anil Dolgun; Berrin Bercik Inal; Aydin Turkmen
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

3.  Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients.

Authors:  Gülcan Güneş; Nil Doğruer Ünal; Gülçin Eskandari; Ahmet Kiykim; Özlem Bölgen Çimen; Gülhan Temel; Mehmet Burak Y Çimen
Journal:  Int Urol Nephrol       Date:  2018-04-11       Impact factor: 2.370

4.  Trabecular bone deterioration at the greater trochanter of mice with unilateral obstructive nephropathy.

Authors:  Sa-Sa Gu; Yan Zhang; Xi Chen; Teng-Yue Diao; Yoseph Gebru; Man-Sau Wong
Journal:  Asian J Androl       Date:  2013-05-06       Impact factor: 3.285

5.  Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.

Authors:  Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Seung Hyeok Han; Kyu Hun Choi; Joongyub Lee; Dong Wan Chae; Kook-Hwan Oh; Curie Ahn; Soo Wan Kim
Journal:  PLoS One       Date:  2016-11-17       Impact factor: 3.240

6.  An Investigation Into the Role of Osteocalcin in Human Arterial Smooth Muscle Cell Calcification.

Authors:  Sophie A Millar; Stephen G John; Christopher W McIntyre; Vera Ralevic; Susan I Anderson; Saoirse E O'Sullivan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-10       Impact factor: 5.555

7.  A biomarker, osteoprotegerin, in patients undergoing hemodialysis.

Authors:  Gang Jee Ko
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

8.  Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.

Authors:  Anna Gluba-Brzózka; Marta Michalska-Kasiczak; Beata Franczyk; Marek Nocuń; Peter Toth; Maciej Banach; Jacek Rysz
Journal:  Lipids Health Dis       Date:  2016-02-03       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.